Sutro Biopharma (STRO) Stock Analysis & AI Equity Report
Sutro Biopharma (STRO) overview
Sutro Biopharma (STRO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 102m and operating profit of USD -158m; the year-end share price was 11.57 USD and market capitalisation was USD 99.3m. Sutro Biopharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Sutro Biopharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Sutro Biopharma
Sutro Biopharma is a clinical-stage oncology company developing antibody-drug conjugates using its cell-free protein synthesis and site-specific conjugation platforms. Its pipeline includes candidates directed at tumor targets, including a clinical-stage candidate for solid tumors. The company also collaborates with pharmaceutical and biotechnology partners on antibody-based drug discovery and development, and its platforms have supported vaccine research and development.
Generate the Sutro Biopharma report
Sutro Biopharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Sutro Biopharma and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Sutro Biopharma
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.